At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 75 enrolled
Drug / intervention
Quetiapine and placebo +1 moredrug
Likely dose
Quetiapine and placebo 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents
In Brief
A Phase 4 clinical trial evaluating Quetiapine and placebo and Quetiapine and Topiramate for Bipolar Disorder and Cannabis-Related Disorder. Completed, enrolled 75 participants across 1 site.
Detailed Summary
The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder, Cannabis-Related Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartNov 2006
Primary CompletionDec 2011
Study CompletionMar 2014
TodayJul 2026
First PostedOct 31, 2006
Enrollment StartNov 1, 2006
Primary CompletionDec 1, 2011
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 19.7 years ago
Interventions
Quetiapine and placebodrug
placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
Quetiapine and Topiramatedrug
topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).